Schistosoma mansoni: Identification and Validation of New Targets for Therapy Using a siRNA Screen
Sponsor: World Health Organization (WHO)
Location(s): United States
The possible emergence of resistance to the only available drug for schistosomiasis spurs drug discovery that has been recently incentivized by the availability of improved transcriptome and genome sequence information. Transient RNAi has emerged as a straightforward and important technique to interrogate that information through decreased or loss of gene function and identify potential drug targets.